LOS GATOS, Calif., Nov. 21, 2023 /PRNewswire/ — Supira Medical, Inc., a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD). This approval comes as the company closed $40M in Series D financing and prepares […]
Coronary/Structural Heart
Arineta Receives FDA Clearance for its Deep Learning Image Reconstruction Technology in SpotLight™ Cardiovascular CT Scanners
Caesarea, Israel – November 20, 2023 – Arineta Cardio Imaging, a leader in point-of-care cardiovascular CT solutions, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its deep learning image reconstruction (DLIR) technology for use in its SpotLight™ family of cardiovascular CT (CCT) scanners. This next-generation […]
Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA),
Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry […]
Flow Therapy and The Christ Hospital Presenting the Results of EECP® on Angina with No Obstructive Coronary Arteries (ANOCA)
Patients undergoing non-invasive treatment show significant improvement in frequency of chest pain, exercise capacity and quality-of-life markers FORT WORTH, Texas, Nov. 15, 2023 /PRNewswire/ — Enhanced External Counterpulsation (EECP®), a non-invasive treatment that increases blood…
LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease
CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD. These two trials are part of the registration-enabling Phase 3 LIBerate Pro
New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)
Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen continues commitment to supporting PAD patients with ongoing…
American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI
Caristo’s AI Technology for Coronary Inflammation Measurement and Risk Assessment Can Transform Risk Stratification and Management of Patients PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ — New research, presented today at the American Heart Association’s Late Breaking Science Sessions, has…
Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
DENVER – November 11, 2023 – Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to […]
Multicenter Validation of the Novel Vivio® System for Non-Invasive Estimation of Elevated Left Ventricular End Diastolic Pressure
PASADENA, Calif., Nov. 13, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider focused on cardiovascular health, has announced data presented Saturday, November 11, at the American Heart Association (AHA) Scientific Symposium highlighting a pivotal study demonstrating validation of a noninvasive brachial cuff-ECG system for estimation of elevated left ventricular […]
Recent
New Study Highlights Safety and Efficacy Profile of Haemonetics’ VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)
Reflow Medical Announces U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters
Popular
- No commented posts yet